Tumor Response in the Targeted Population Through the End of Treatment [clinicaltrials_resource:NCT00073008/outcome/1]
outcome [clinicaltrials_vocabulary:outcome]
Tumor Response in the Targeted Population Through the End of Treatment [clinicaltrials_resource:NCT00073008/outcome/1]
Bio2RDF identifier
NCT00073008/outcome/1
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT00073008/outcome/1
analysis [clinicaltrials_vocabulary:analysis]
group [clinicaltrials_vocabulary:group]
measure [clinicaltrials_vocabulary:measure]
population [clinicaltrials_vocabulary:population]
Non-Targeted Population: all r ...... on in the Targeted Population.
Targeted Population
Targeted Population: all rando ...... small cell lung cancer (NSCLC)
safety issue [clinicaltrials_vocabulary:safety-issue]
time frame [clinicaltrials_vocabulary:time-frame]
Anytime from Baseline through end of study
Baseline and then every 4 weeks through end of treatment
Baseline and then every 8 weeks through end of treatment
From randomization and then every 8 weeks to disease progression or death
From randomization and then every 8 weeks to time of response to study drug
From randomization and then every 8 weeks up to four months
From randomization and then ev ...... onths as follow-up until death
From randomization at every 4-week assessment through end of treatment
From randomization to disease ...... alyses of tumor tissue samples
From randomization to time of ...... participant was on study drug
type [clinicaltrials_vocabulary:type]
Other Pre-specified
alternate
Tumor Response in the Targeted Population Through the End of Treatment
@en
identifier
clinicaltrials_resource:NCT00073008/outcome/1
title
Disease progression and tumor ...... cipant discontinued treatment.
@en
type
label
Tumor Response in the Targeted ...... esource:NCT00073008/outcome/1]
@en